Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial
Alvin F. Wells, Christopher J Edwards, Alan Kivitz, et al.
Lara D. Veeken (2018) Vol. 57, Iss. 7, pp. 1253-1263
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 700.1-712
Open Access | Times Cited: 834
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Philip J. Mease, Laura C. Coates, Philip Helliwell, et al.
The Lancet (2018) Vol. 392, Iss. 10162, pp. 2367-2377
Open Access | Times Cited: 188
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis
Andreas Kerschbaumer, Josef S Smolen, Maxime Dougados, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 778-786
Open Access | Times Cited: 169
Psoriatic Arthritis: Pathogenesis and Targeted Therapies
Ana Belén Azuaga, Julio Ramírez, Juan D. Cañete
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4901-4901
Open Access | Times Cited: 76
Psoriatic arthritis
Vanessa Ocampo D, Dafna D. Gladman
F1000Research (2019) Vol. 8, pp. 1665-1665
Open Access | Times Cited: 144
Inflammatory Cytokines in Psoriatic Arthritis: Understanding Pathogenesis and Implications for Treatment
Bong-Woo Lee, Su‐Jin Moon
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11662-11662
Open Access | Times Cited: 31
Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology
Elena Carmona‐Rocha, Lluís Rusiñol, L. Puig
Pharmaceutics (2025) Vol. 17, Iss. 1, pp. 91-91
Open Access | Times Cited: 1
Pathophysiology, assessment and treatment of psoriatic dactylitis
Dennis McGonagle, Ai Lyn Tan, ‬‬‬‬Abdulla Watad, et al.
Nature Reviews Rheumatology (2019) Vol. 15, Iss. 2, pp. 113-122
Closed Access | Times Cited: 57
Apremilast in psoriasis and beyond: Big hopes on a small molecule
Sunil Dogra, T. P. Afra, TMuhammed Razmi
Indian Dermatology Online Journal (2019) Vol. 10, Iss. 1, pp. 1-1
Open Access | Times Cited: 57
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
Philip J. Mease, Iain B. McInnes, Lai‐Shan Tam, et al.
Lara D. Veeken (2021) Vol. 60, Iss. 5, pp. 2109-2121
Open Access | Times Cited: 56
Hydrogen Sulfide as Potential Regulatory Gasotransmitter in Arthritic Diseases
Flavia Sunzini, Susanna De Stefano, Maria Sole Chimenti, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 4, pp. 1180-1180
Open Access | Times Cited: 52
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
Philip J. Mease, Gülen Hatemi, Maria Paris, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 5, pp. 809-820
Open Access | Times Cited: 18
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
Luca Richeldi, Arata Azuma, Vincent Cottin, et al.
BMJ Open Respiratory Research (2023) Vol. 10, Iss. 1, pp. e001563-e001563
Open Access | Times Cited: 18
Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors
Gerasimos Evangelatos, Vasiliki Koulouri, Alexios Iliopoulos, et al.
Therapeutic Advances in Musculoskeletal Disease (2020) Vol. 12
Open Access | Times Cited: 41
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis
Lihi Eder, Sivakami Mylvaganam, Jordi Pardo Pardo, et al.
The Lancet Rheumatology (2023) Vol. 5, Iss. 12, pp. e716-e727
Closed Access | Times Cited: 15
Pharmacologic Treatment Strategies in Psoriatic Arthritis
Gizem Ayan, André Lucas Ribeiro, Betul Macit, et al.
Clinical Therapeutics (2023) Vol. 45, Iss. 9, pp. 826-840
Open Access | Times Cited: 12
Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study
Vinod Chandran, Louis Bessette, J. Carter Thorne, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 2, pp. 443-455
Open Access | Times Cited: 4
Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN‐FRT expert consensus
Tiago Torres, Nicolò Costantino Brembilla, Richard Langley, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 4
Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 5, pp. 837-847
Open Access | Times Cited: 10
Comorbid Infections in Spondyloarthritis: the Current State of the Problem
М. М. Баранова, N. V. Muravyevа, Б. С. Белов
Antibiot Khimioter = Antibiotics and Chemotherapy (2025) Vol. 69, Iss. 11-12, pp. 127-135
Open Access
Real-World Effectiveness and Tolerability of Apremilast in Psoriatic Arthritis in Germany: Results from LAPIS-PsA
Frank Behrens, J. Wollenhaupt, Michael Fiene, et al.
The Open Rheumatology Journal (2025) Vol. 19, Iss. 1
Open Access
Defining Pre-Clinical Psoriatic Arthritis in an Integrated Dermato-Rheumatology Environment
L. Savage, Ilaria Tinazzi, Alen Zabotti, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 10, pp. 3262-3262
Open Access | Times Cited: 27
Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
Pascal Richette, Marijn Vis, Sarah Ohrndorf, et al.
RMD Open (2023) Vol. 9, Iss. 1, pp. e002934-e002934
Open Access | Times Cited: 9
Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post‐marketing surveillance study
Mamitaro Ohtsuki, Yukari Okubo, Hidehisa Saeki, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 7, pp. 950-963
Open Access | Times Cited: 3
Multimodal Imaging of Structural Damage and Inflammation in Psoriatic Arthritis: A comparison of DMARD-Naive and DMARD-Failure Patients
Nağme Ö Renkli, Nienke J. Kleinrensink, Julia Spierings, et al.
Lara D. Veeken (2024)
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top